Abstract 1877
Background
Based on mRNA expression, accRCC can be divided in four molecular subtypes (ccrcc1-4), associated with prognosis, angiogenic signature, immune phenotype and therapy response. miRNAs are master regulators of mRNA function. We assessed the correlation of miRNA expression with (1) ccrccc1-4 subtypes, (2) mRNA targets and (3) outcome.
Methods
We performed miRNome analysis of 128 accRCC. (1) Unsupervised hierarchical clustering was done using 50 miRNAs with the most variable expression across all samples. Results were validated on TCGA data (n = 255). (2) For miRNAs with subtype-specific expression, we performed pathway analysis of predicted mRNA targets (IPA, KEGG) and assessed target-downregulation in TCGA. (3) We used Cox regression to correlate miRNA expression with overall survival (OS) since diagnosis. Hazard ratios (HR) were correlated with subtype-specific expression (Pearson).
Results
(1) Samples separated in two miRNA clusters, that partially overlapped with molecular subtypes. Cluster 1 consisted of 69% favourable subtypes (ccrcc2 or 3), cluster 2 of 77% unfavourable (ccrcc1 or 4) (p < 2.2e-16). (2) Pathway analysis of predicted mRNA targets and targets suppressed in TCGA, suggested that favourable subtypes exhibit more angiogenic signaling, whereas unfavourable subtypes activate pathways involved in tumor invasiveness. (3) Several miRNAs were significantly associated with OS. There was a robust correlation in the entire dataset between HR for OS and differential expression between favourable/unfavourable subtypes (r = 0.322; p < 0.0001).Table:
973P
miRNA | Subtype-specific expression log2FoldChange <0: higher in ccrcc1 or -4 (unfavourable) log2FoldChange >0: higher in ccrcc2 or -3 (favourable) | *p<0.05 ** false discovery rate <0.05 | Overall survival (hazard ratio) | |
---|---|---|---|---|
182-5p | -1,43 | ** | 1,25 | ** |
3529-3p | -1,42 | ** | 1,37 | ** |
335-3p | -1,33 | ** | 1,25 | ** |
34c-5p | -1,22 | ** | 1,25 | ** |
193b-3p | -1,17 | ** | 1,31 | ** |
370-3p | -1,07 | ** | 1,16 | ** |
199b-5p | -1,05 | ** | 1,26 | ** |
21-3p | -0,89 | ** | 1,47 | ** |
574-5p | -0,89 | ** | 1,40 | ** |
4792 | -0,88 | ** | 0,88 | * |
let-7i-5p | -0,81 | ** | 1,66 | ** |
652-3p | -0,75 | ** | 1,39 | ** |
1301-3p | -0,70 | ** | 1,39 | ** |
222-3p | -0,66 | ** | 1,31 | * |
320a | -0,63 | ** | 1,28 | ** |
425-5p | -0,62 | ** | 1,66 | ** |
149-5p | -0,61 | ** | 1,32 | * |
146b-5p | -0,54 | * | 1,49 | ** |
193b-5p | -0,49 | 1,21 | ** | |
185-5p | -0,49 | ** | 1,42 | ** |
21-5p | -0,42 | * | 1,68 | ** |
7641 | -0,33 | 0,80 | ** | |
320b | -0,28 | 1,25 | ** | |
1260b | -0,15 | 0,79 | ** | |
4454 | 0,15 | 0,80 | ** | |
6880-5p | 0,25 | 0,64 | ** | |
27b-3p | 0,36 | ** | 0,71 | * |
1260a | 0,38 | 0,73 | ** | |
7977 | 0,39 | 0,73 | ** | |
23b-3p | 0,48 | ** | 0,81 | ** |
2392 | 0,55 | 0,80 | ** | |
194-5p | 0,55 | * | 0,74 | ** |
30c-5p | 0,70 | ** | 0,78 | * |
190a-5p | 0,86 | ** | 0,83 | ** |
204-5p | 1,23 | ** | 0,71 | ** |
135a-5p | 1,37 | ** | 0,86 | ** |
Conclusions
accRCC molecular subtypes exhibit different miRNA expression patterns. Differentially expressed miRNAs are implicated in pathways driving tumor biology and strongly correlated with OS. These findings underscore the robustness of the molecular subtypes and are, to the best of our knowledge, the first to show an association of global miRNome expression with outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Fonds Wetenschappelijk Onderzoek Vlaanderen.
Disclosure
M. Albersen: Research grant / Funding (self): Ipsen. B. Beuselinck: Advisory / Consultancy, Research grant / Funding (self): Bristol Meyers Squibb; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Merck; Research grant / Funding (self): Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
4543 - Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study
Presenter: Stéphane Dalle
Session: Poster Display session 3
Resources:
Abstract
4523 - Prognostic Factors for efficacy of Ipilimumab used after AntiPD1 and/or BRAF+MEK inhibitors in Melanoma Patients: an Italian Melanoma Intergroup study
Presenter: Riccardo Marconcini
Session: Poster Display session 3
Resources:
Abstract
3632 - Rechallenge with combination ipilimumab and anti-PD-1 (IPI+PD1) in metastatic melanoma after acquired resistance to IPI+PD1 immunotherapy
Presenter: Adriana Hepner
Session: Poster Display session 3
Resources:
Abstract
3732 - Clinicopathologic characteristics of immune colitis in melanoma patients treated with combination ipilimumab and anti-PD1 (IPI+PD1) and PD1 monotherapy.
Presenter: Kazi Nahar
Session: Poster Display session 3
Resources:
Abstract
5005 - Real-world outcomes of ipilimumab plus nivolumab for advanced melanoma in the Netherlands
Presenter: Michiel van Zeijl
Session: Poster Display session 3
Resources:
Abstract
5524 - Utilization of Real-World Data to Assess the Effectiveness of Immune Checkpoint Inhibitors (ICIs) in Elderly Patients with Metastatic Melanoma
Presenter: D Scott Ernst
Session: Poster Display session 3
Resources:
Abstract
5884 - Tumor mutational burden and response to PD-1 inhibitors: an analysis of 89 cases of metastatic melanoma.
Presenter: Léa Dousset
Session: Poster Display session 3
Resources:
Abstract
3120 - Increase in S100B and LDH as early outcome predictors for non-responsiveness to anti-PD-1 monotherapy in advanced melanoma.
Presenter: Elisa Rozeman
Session: Poster Display session 3
Resources:
Abstract
2157 - Immune status defined by molecular information layers predicts response to pembrolizumab treatment in advanced melanoma
Presenter: Guillermo Prado-Vázquez
Session: Poster Display session 3
Resources:
Abstract
2553 - Interim analysis of a phase Ib study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild type melanoma progressing on prior anti-PD-L1 therapy
Presenter: Shahneen Sandhu
Session: Poster Display session 3
Resources:
Abstract